361 related articles for article (PubMed ID: 8622988)
1. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
Cheng JQ; Ruggeri B; Klein WM; Sonoda G; Altomare DA; Watson DK; Testa JR
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3636-41. PubMed ID: 8622988
[TBL] [Abstract][Full Text] [Related]
2. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas.
Ruggeri BA; Huang L; Wood M; Cheng JQ; Testa JR
Mol Carcinog; 1998 Feb; 21(2):81-6. PubMed ID: 9496907
[TBL] [Abstract][Full Text] [Related]
3. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer.
Miwa W; Yasuda J; Murakami Y; Yashima K; Sugano K; Sekine T; Kono A; Egawa S; Yamaguchi K; Hayashizaki Y; Sekiya T
Biochem Biophys Res Commun; 1996 Aug; 225(3):968-74. PubMed ID: 8780719
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Bellacosa A; de Feo D; Godwin AK; Bell DW; Cheng JQ; Altomare DA; Wan M; Dubeau L; Scambia G; Masciullo V; Ferrandina G; Benedetti Panici P; Mancuso S; Neri G; Testa JR
Int J Cancer; 1995 Aug; 64(4):280-5. PubMed ID: 7657393
[TBL] [Abstract][Full Text] [Related]
5. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.
Cheng JQ; Godwin AK; Bellacosa A; Taguchi T; Franke TF; Hamilton TC; Tsichlis PN; Testa JR
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9267-71. PubMed ID: 1409633
[TBL] [Abstract][Full Text] [Related]
6. Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene.
Altomare DA; Guo K; Cheng JQ; Sonoda G; Walsh K; Testa JR
Oncogene; 1995 Sep; 11(6):1055-60. PubMed ID: 7566964
[TBL] [Abstract][Full Text] [Related]
7. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis.
Cheng JQ; Altomare DA; Klein MA; Lee WC; Kruh GD; Lissy NA; Testa JR
Oncogene; 1997 Jun; 14(23):2793-801. PubMed ID: 9190895
[TBL] [Abstract][Full Text] [Related]
8. Frequent activation of AKT2 kinase in human pancreatic carcinomas.
Altomare DA; Tanno S; De Rienzo A; Klein-Szanto AJ; Tanno S; Skele KL; Hoffman JP; Testa JR
J Cell Biochem; 2002; 87(4):470-6. PubMed ID: 14735903
[TBL] [Abstract][Full Text] [Related]
9. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
Shi XH; Liang ZY; Ren XY; Liu TH
Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
[TBL] [Abstract][Full Text] [Related]
10. Antisense and dominant-negative AKT2 cDNA inhibits glioma cell invasion.
Pu P; Kang C; Li J; Jiang H
Tumour Biol; 2004; 25(4):172-8. PubMed ID: 15557754
[TBL] [Abstract][Full Text] [Related]
11. Chromosome mapping of the mouse Akt2 gene and Akt2 pseudogene.
Altomare DA; Kozak CA; Sonoda G; Testa JR
Cytogenet Cell Genet; 1996; 74(4):248-51. PubMed ID: 8976376
[TBL] [Abstract][Full Text] [Related]
12. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells.
Kleeff J; Wildi S; Kumbasar A; Friess H; Lander AD; Korc M
Pancreas; 1999 Oct; 19(3):281-8. PubMed ID: 10505759
[TBL] [Abstract][Full Text] [Related]
13. Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.
Tang YC; Li Y; Qian GX
World J Gastroenterol; 2001 Feb; 7(1):22-7. PubMed ID: 11819727
[TBL] [Abstract][Full Text] [Related]
14. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines.
Tang TC; Sham JS; Xie D; Fang Y; Huo KK; Wu QL; Guan XY
Cancer Res; 2002 Dec; 62(24):7157-61. PubMed ID: 12499249
[TBL] [Abstract][Full Text] [Related]
15. The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo.
Pu P; Kang C; Li J; Jiang H; Cheng J
J Neurooncol; 2006 Jan; 76(1):1-11. PubMed ID: 16402276
[TBL] [Abstract][Full Text] [Related]
16. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Arber N; Doki Y; Han EK; Sgambato A; Zhou P; Kim NH; Delohery T; Klein MG; Holt PR; Weinstein IB
Cancer Res; 1997 Apr; 57(8):1569-74. PubMed ID: 9108461
[TBL] [Abstract][Full Text] [Related]
17. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies.
Thompson FH; Nelson MA; Trent JM; Guan XY; Liu Y; Yang JM; Emerson J; Adair L; Wymer J; Balfour C; Massey K; Weinstein R; Alberts DS; Taetle R
Cancer Genet Cytogenet; 1996 Mar; 87(1):55-62. PubMed ID: 8646743
[TBL] [Abstract][Full Text] [Related]
18. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
[TBL] [Abstract][Full Text] [Related]
19. [Effects of antisense cyclin D1 expressing vector on the cell growth and apoptosis of pancreatic carcinoma].
Xu Y; Liu T; Gao J
Zhonghua Bing Li Xue Za Zhi; 1998 Oct; 27(5):348-51. PubMed ID: 11245009
[TBL] [Abstract][Full Text] [Related]
20. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
Burfeind P; Chernicky CL; Rininsland F; Ilan J; Ilan J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7263-8. PubMed ID: 8692980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
